# Inovio Pharmaceuticals

Source: https://onco.cc/companies/inovio/  
OnCo record `inovio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Inovio is a US company developing DNA medicines delivered by electroporation, whose lead cancer-related programme VGX-3100 treats the HPV-caused precancerous cervical lesions that lead to cervical cancer.

## Summary

Inovio Pharmaceuticals, listed on Nasdaq, develops DNA plasmid immunotherapies and vaccines delivered into muscle or skin with a hand-held electroporation device. Its most advanced programme, VGX-3100, targets HPV 16 and 18 to clear high-grade cervical dysplasia (CIN2/3), the precancerous lesion that precedes cervical cancer, and completed the phase 3 REVEAL trials; the company has also run trials of DNA vaccines in HPV-related head and neck and anal cancers and in glioblastoma. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Inovio; INOVIO Pharmaceuticals, Inc.
- Tags: ctgov-sponsor
- HQ: Plymouth Meeting, PA
- Type: biotech
- Website: https://www.inovio.com

## Sources

- Official website: https://www.inovio.com
- ClinicalTrials.gov: trials led by Inovio Pharmaceuticals: https://clinicaltrials.gov/search?lead=Inovio%20Pharmaceuticals
- Wikipedia: https://en.wikipedia.org/wiki/Inovio_Pharmaceuticals

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Prevention & Risk](https://onco.cc/fronts/prevention/)

---
JSON: https://onco.cc/api/v1/entities/inovio.json